<DOC>
	<DOCNO>NCT02423785</DOCNO>
	<brief_summary>In colorectal cancer therapy anti-angiogenic strategy become cornerstone treatment regimen metastatic setting . Addition bevacizumab conventional chemotherapeutic combination regimens improved median overall survival advance colorectal cancer patient approximately 5 month . Selecting patient , benefit anti-angiogenic approach , would highly desirable order optimize treatment strategy . Changes ocular blood flow may attractive biomarker predict treatment response . In light give alternative first line treatment option predictive biomarker would clinical benefit . In proposed study investigator assess potential change ocular blood flow mCRC patient treatment standard care anti-angiogenic/cytotoxic therapy early predictive marker treatment response assess standard CT-scan</brief_summary>
	<brief_title>Ocular Blood Flow Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Male female patient ( age 18 ) suffering mCRC . Normal finding ophthalmic examination ( except investigator find abnormality irrelevant purpose study . ) Patients , schedule standard care treatment chemotherapy plus bevacizumab Refusal give inform consent Severe hypertension ( RR â‰¥180/110 ) Epilepsy Pregnancy breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>